|
|
 |
|
Viewing report
|
|
|
|
Cancer Biomarkers: New Tools for Transforming Cancer Management
Decision Resources, Inc., April 2007, Pages: 34
Although novel cancer biomarkers are reported on a weekly basis, only a handful are actually translated into fully validated diagnostic tools. To fully understand the process, we explore the current status of the cancer biomarker field, roadblocks that slow the development process, the cancer biomarker pipeline, as well as the outlook for integrating cancer biomarkers into clinical practice. We also profile select companies that are actively pursuing cancer biomarker discovery and development.
Get the Answers You Need to Shape Your Strategy
- Companies are utilizing cutting-edge technologies to develop, validate, and implement cancer biomarkers for clinical use. What impediments still exist to incorporating promising research into clinical practice? Which biomarkers show the most promise for approval?
- Integrating cancer biomarkers into clinical practice is the goal for development companies as well as clinicians.
- What are the economic challenges to approval? How can regulatory oversight drive approval and adoption of new technologies? No one company or agency has the necessary scope or expertise to drive the discovery, development, and implementation of sensitive and specific biomarkers. Which alliances show the greatest synergy in bringing valid biomarkers to market? Which shared technologies are driving the most encouraging development?
Scope
- Trends in Cancer Biomarker Development: Biomarker discovery and validation, as well as the role of the diagnostics.
- Emerging Biomarkers in Select Cancers: Bladder, breast, colorectal, lung, pancreatic, prostate, and renal cell.
- Profiles of Select Cancer Biomarker Companies: Biomarker Technologies, Ciphergen, Claros Diagnostics, Epigenomics, Exagen Diagnostics, Genesis Genomics, Health Discovery Corporation, Ipsogen, Matritech, Miraculins, Orion Genomics, Phenomenone Discoveries, Power3 Medical Products, Upstream Biosciences.
- Challenges: How strategic alliances and interdisciplinary involvement will need to drive development and implementation of emerging biomarker technologies.
Customers who bought this item also bought
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Biomarkers - Technologies, Markets and Companies
Cancer Biomarkers: Players, Products and Prospects (Volume I)
Cancer, CNS & Cardiovascular Biomarkers: Players, Products and Prospects
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
Biomarkers 2008
Advances in Biomarkers
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Companion Biomarkers in Drug Development
Biomarkers - Advanced Technologies and Global Market (2009-2014)
Cancer Biomarkers Conference 2008
Biomarkers: The Future of Next-Generation Drug R&D
|
|
|
|
